Rosiglitazone (Molecule of the Month for May 2007)
Avandia, Avandamet, Avandaryl, rosiglitazone maleate
Rosiglitazone is an anti-diabetic drug from the thiazolidinedione class. It is being marketed as Avandia by the pharmaceutical company GlaxoSmithKline. Rosiglitazone acts primarily by increasing insulin sensitivity. Avandia is used in the management of type 2 diabetes mellitus. Rosiglitazone is an anti-diabetic drug from the thiazolidinedione class. Avandia improves glycemic control while reducing circulating insulin levels.
Pharmacological studies in animal models indicate that rosiglitazone improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis.
A February 2007 press release by GlaxoSmithKline notes a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. In May 2007, an article in the New England Journal of Medicine tied the use of rosiglitazone to a 45% increased risk of heart attack.
Update by Karl Harrison
(Molecule of the Month for May 2007 )